- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 11.12.25 | SINOMAB BIO-B (03681): VOLUNTARY ANNOUNCEMENT IND APPLICATION FOR SM17 ACCEPTED BY NMPA CDE | - | HKEx | ||
| 14.10.25 | SINOMAB BIO-B (03681): VOLUNTARY ANNOUNCEMENT FIRST COHORT OF HEALTHY SUBJECTS DOSED WITH SUBCUTANEOUS FORMULATION OF SM17 IN A BRIDGING STUDY IN CHINA | - | HKEx | ||
| 08.10.25 | SINOMAB BIO-B (03681): CHANGE OF COMPANY SECRETARY | 1 | HKEx | ||
| SINOMAB BIOSCIENCE Aktie jetzt für 0€ handeln | |||||
| 26.09.25 | SINOMAB BIO-B (03681): NOTIFICATION LETTER TO NON-REGISTERED SHAREHOLDERS AND REPLY FORM | 2 | HKEx | ||
| 26.09.25 | SINOMAB BIO-B (03681): NOTIFICATION LETTER TO REGISTERED SHAREHOLDERS AND REPLY FORM | - | HKEx | ||
| 26.09.25 | SINOMAB BIO-B (03681): INTERIM REPORT 2025 | - | HKEx | ||
| 29.08.25 | SINOMAB BIO-B (03681): INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED 30 JUNE 2025 | - | HKEx | ||
| 29.08.25 | SINOMAB BIO-B (03681): NEXT DAY DISCLOSURE RETURN | 1 | HKEx | ||
| 29.08.25 | SINOMAB BIO-B (03681): COMPLETION OF SUBSCRIPTIONS OF NEW SHARES UNDER GENERAL MANDATE | - | HKEx | ||
| 18.08.25 | SINOMAB BIO-B (03681): DATE OF BOARD MEETING | 1 | HKEx | ||
| 15.08.25 | SINOMAB BIO-B (03681): NEXT DAY DISCLOSURE RETURN | 3 | HKEx | ||
| 15.08.25 | SINOMAB BIO-B (03681): COMPLETION OF CERTAIN SUBSCRIPTIONS OF NEW SHARES UNDER GENERAL MANDATE | 1 | HKEx | ||
| 12.08.25 | SINOMAB BIO-B (03681): VOLUNTARY ANNOUNCEMENT COMPREHENSIVE STRATEGIC COOPERATION AGREEMENT | 1 | HKEx | ||
| 24.07.25 | SINOMAB BIO-B (03681): GRANT OF SHARE OPTIONS | 1 | HKEx | ||
| 22.07.25 | SINOMAB BIO-B (03681): SUBSCRIPTIONS OF NEW SHARES UNDER GENERAL MANDATE | 3 | HKEx | ||
| 09.04.25 | SinoMab BioScience Limited Breakthrough Phase 1b POC Results for SM17 in Atopic Dermatitis | 481 | JCN Newswire | - Potentially a First-and Best-in-Class Product- Combining Deep Pruritus Relief, Effective Skin Clearance, and a Well-tolerated Safety ProfileHONG KONG, Apr 9, 2025 - (ACN Newswire) - SinoMab BioScience... ► Artikel lesen |
16 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PRAXIS PRECISION MEDICINES | 280,83 | +1,85 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Further Positioned for Next-Phase Growth with Key Board and Executive Appointments | BOSTON, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies... ► Artikel lesen | |
| STRUCTURE THERAPEUTICS | 77,92 | 0,00 % | Structure Therapeutics Inc.: Structure Therapeutics Announces Initiation of Phase 1 Clinical Study of Oral Small Molecule Amylin Receptor Agonist ACCG-2671 for the Treatment of Obesity | SAN FRANCISCO, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for... ► Artikel lesen | |
| IMMUNOME | 20,140 | -2,09 % | Immunome: Guggenheim bestätigt Kaufempfehlung nach 400-Millionen-Dollar-Finanzierung | ||
| BEAM THERAPEUTICS | 34,550 | +2,55 % | AKTIONÄR-Tipp Beam Therapeutics wie entfesselt: Die Hintergründe! | Innerhalb der Biotech-Branche zählt der Bereich Gen-Schere zu den absoluten Top-Trends. Neben der wohlbekanntesten seiner Klasse, CRISPR/Cas9, entwickeln sich auch andere Ansätze weiter. Dazu zählt... ► Artikel lesen | |
| BIONTECH | 92,05 | 0,00 % | +23 % Kursplus in wenigen Tagen! DroneShield, BioNTech, WashTec Aktie! | Über 23 % hat die Aktie von DroneShield in den ersten Handelstagen des Jahres bereits zulegen können. Rückenwind erhält der Spezialist für Drohnenabwehr durch zwei Aufträge kurz vor dem Jahreswechsel.... ► Artikel lesen | |
| QIAGEN | 40,415 | -1,26 % | QIAGEN - hält was es verspricht | Das Unternehmen aus Hilden hat seine Prognosen im abgelaufenen Geschäftsjahr erreicht. Nun geht es optimistisch in das neue Jahr, in dem es sich auf die Förderung der Produktvermarktung, regulatorische... ► Artikel lesen | |
| VERA THERAPEUTICS | 49,100 | 0,00 % | Vera Therapeutics Announces U.S. FDA Granted Priority Review to Biologics License Application for Atacicept for Treatment of Adults with IgA Nephropathy | FDA assigned PDUFA target action date of July 7, 2026.If approved, atacicept would be the first B cell modulator targeting both BAFF and APRIL for IgAN.Atacicept received FDA Breakthrough Therapy... ► Artikel lesen | |
| ADMA BIOLOGICS | 17,700 | -1,28 % | ADMA Biologics Reports Preliminary 2025 Results, Ups 2026 Outlook | ||
| ALUMIS | 22,110 | 0,00 % | Alumis Inc.: Alumis Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares | SOUTH SAN FRANCISCO, Calif., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing next-generation targeted therapies for patients with... ► Artikel lesen | |
| COGENT BIOSCIENCES | 35,280 | +1,50 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Anticipated 2026 Commercial and Clinical Milestones for Bezuclastinib and Precision Therapies Portfolio | New Drug Application (NDA) for NonAdvSM submitted in December 2025, NDA submission for AdvSM on track for 1H 2026NDA submission for GIST on track for April 2026; bezuclastinib has the potential to... ► Artikel lesen | |
| KYMERA THERAPEUTICS | 74,13 | 0,00 % | Kymera Therapeutics, Inc.: Kymera Therapeutics Outlines Key 2026 Objectives and Strategy to Advance Industry Leading Portfolio of Oral Immunology Programs | KT-621 BROADEN2 Phase 2b trial in AD ongoing, with data expected by mid-2027 KT-621 BREADTH Phase 2b trial in asthma initiated, with data expected in late-2027 KT-579 Phase 1 HV clinical trial expected... ► Artikel lesen | |
| MINERALYS THERAPEUTICS | 32,940 | -0,12 % | Mineralys Therapeutics, Inc.: Mineralys Therapeutics' Phase 3 Launch-HTN Trial of Lorundrostat Recognized in Inaugural Journal of the American Medical Association (JAMA) "Research of the Year" Roundup | - Launch-HTN, the largest trial of an aldosterone synthase inhibitor conducted among participants with uncontrolled or treatment-resistant hypertension, was one of nine studies selected as most impactful... ► Artikel lesen | |
| HARMONY BIOSCIENCES | 35,760 | -6,56 % | Harmony Biosciences: WAKIX-Umsatz soll 2026 die Marke von 1 Milliarde US-Dollar übersteigen | ||
| DYNE THERAPEUTICS | 17,040 | -2,41 % | Dyne Therapeutics, Inc. - 8-K, Current Report | ||
| ARCELLX | 66,75 | +2,90 % | UBS initiates Arcellx stock coverage with Buy rating, $100 price target |
Das Unternehmen SINOMAB BIOSCIENCE LTD kann der Branche Biotechnologie zugeordnet werden.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SINOMAB BIOSCIENCE LTD finden Sie auf Wallstreet Online.